INDSWFTLAB379.00

Ind-Swift Laboratories Limited

· Pharma & Health
₹ CrorePeersSMSPHARMASOLARADCALHIKALUNICHEMLABGUFICBIOPANACEABIORPGLIFEMcap ₹3,291 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation53.324.530.6
+ Impairment Loss / (Reversal)0.00.0-1.4
+ Finance Costs45.10.00.0
+ Unrealised FX (Gain) / Loss-2.50.0-4.8
+ Other Non-cash Items-0.0-223.222.0
+ Other — Cash Effects are Investing / Financing-386.60.0-55.3
Changes in Working Capital
+ Inventories32.9-43.2-33.8
+ Trade Receivables — Current-130.096.8-40.3
+ Other Current Assets-436.5-6.4-76.0
+ Other Non-current Assets0.0-28.746.7
+ Other Financial Liabilities — Current6.90.00.0
+ Other Current Liabilities26.0-67.00.0
+ Provisions — Current0.03.50.0
+ Provisions — Non-current24.80.00.0
Cash from Operating Activities
Profit Before Tax (per I/S)581.8257.849.071.3
+ Total Adjustments (incl. Working Capital)-766.7-243.7-112.2
Cash from Operations (pre-tax)-185.014.1-63.2
+ Interest Received — Operating-18.4-75.30.0
+ Interest Paid — Operating0.0-39.20.0
+ Other Inflows / (Outflows) — Operating22.50.00.0
+ Income Taxes Paid0.13.30.0
Cash from Operating Activities-180.9-25.5-63.2
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)44.564.487.7
+ Disp of Fixed Assets2.938.61.2
+ Acq of Investment Property0.00.041.6
+ Disp of Investment Property0.0-125.80.0
+ Acq of Subsidiaries / Businesses (net)81.10.00.0
+ Interest Received — Investing18.442.055.5
Cash from Investing Activities-104.3-109.6-72.7
Cash from Financing Activities
+ Proceeds from Issue of Shares0.00.0163.0
+ Proceeds from Other Equity Instruments0.092.60.0
+ Proceeds from Borrowings0.027.60.0
+ Repayment of Borrowings37.46.615.1
+ Payment of Lease Liabilities0.0-0.70.0
+ Interest Paid126.041.95.5
+ Income Taxes (Paid) / Refund — Financing72.83.20.0
+ Other Inflows / (Outflows) — Financing935.20.0-0.6
Cash from Financing Activities698.969.2141.8
Net Changes in Cash (pre-FX)413.7-65.95.9
+ Effect of FX Rate Changes on Cash-0.4-0.65.5
Net Changes in Cash413.3-66.511.4
Closing Cash431.5
Reference Items
EBITDA254.2-19.445.159.7
EBITDA Margin %19.85-3.457.038.97
Free Cash Flow (CFO − Capex)-225.4-89.9-150.9-150.9
Free Cash Flow to Equity-107.8-179.1
Free Cash Flow per Basic Share-25.96-10.35-17.38-17.38
Cash Flow to Net Income-0.43-0.10-1.53
Cash Paid for Taxes0.13.30.0
Cash Paid for Interest126.041.95.5
As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.